{"id":44138,"date":"2026-11-12T08:50:04","date_gmt":"2026-11-12T05:50:04","guid":{"rendered":"https:\/\/kibrisayna.com\/index.php\/2026\/11\/12\/abd-uyardi-ozempic-ve-mounjaro-kor-edebilir-ustelik-tedavisi-de-yok\/"},"modified":"2026-11-12T08:50:04","modified_gmt":"2026-11-12T05:50:04","slug":"abd-uyardi-ozempic-ve-mounjaro-kor-edebilir-ustelik-tedavisi-de-yok","status":"publish","type":"post","link":"https:\/\/kibrisayna.com\/index.php\/2026\/11\/12\/abd-uyardi-ozempic-ve-mounjaro-kor-edebilir-ustelik-tedavisi-de-yok\/","title":{"rendered":"ABD uyard\u0131. Ozempic ve Mounjaro k\u00f6r edebilir, \u00fcstelik tedavisi de yok"},"content":{"rendered":"


\n
\"ABD<\/p>\n

D\u00fcnyada ve T\u00fcrkiye’de kullan\u0131m\u0131 giderek artan zay\u0131flama i\u011fneleri ve ila\u00e7lar\u0131yla ilgili ABD’den bir uyar\u0131 geldi. \u0130la\u00e7lar\u0131n \u00e7ok nadir de olsa g\u00f6rme kayb\u0131na yol a\u00e7abilece\u011fi belirtiliyor.<\/p>\n

Amerika Birle\u015fik Devletleri (ABD) G\u0131da ve \u0130la\u00e7 Dairesi FDA Ozempic<\/a>, Wegovy ve Mounjaro gibi diyabet ve kilo verme tedavisinde kullan\u0131lan ila\u00e7lara yeni bir g\u00fcvenlik uyar\u0131s\u0131 getirdi.<\/p>\n

 <\/p>\n

Buna g\u00f6re \u00fcretici firmalar, nadir g\u00f6r\u00fclmesine ra\u011fmen kal\u0131c\u0131 g\u00f6rme kayb\u0131na yol a\u00e7abilen bir g\u00f6z hastal\u0131\u011f\u0131 riskine ili\u015fkin uyar\u0131lar\u0131, ila\u00e7lar\u0131n g\u00fcvenlik etiketlerine eklemek zorunda olacak.<\/p>\n

 <\/p>\n

NAION ad\u0131 verilen hastal\u0131k, g\u00f6rme sinirini besleyen damarlar\u0131n t\u0131kanmas\u0131 sonucu ortaya \u00e7\u0131kabiliyor.<\/p>\n

 <\/p>\n

G\u00d6RME KAYBININ B\u0130L\u0130NEN TEDAV\u0130S\u0130 DE YOK<\/strong><\/p>\n

 <\/p>\n

Tek g\u00f6zde ani ve a\u011fr\u0131s\u0131z g\u00f6rme kayb\u0131na neden olabiliyor. Hastal\u0131\u011f\u0131n yol a\u00e7t\u0131\u011f\u0131 g\u00f6rme kayb\u0131n\u0131 geri d\u00f6nd\u00fcrebilecek bilinen bir tedavi de bulunmuyor.<\/p>\n

S\u00f6z konusu risk daha \u00f6nce de 2024’te yay\u0131mlanan bilimsel bir \u00e7al\u0131\u015fmayla g\u00fcndeme gelmi\u015fti.<\/p>\n

 <\/p>\n

Ard\u0131ndan 2025’te Avrupa \u0130la\u00e7 Ajans\u0131 da NAION’u Semaglutid i\u00e7eren ila\u00e7lar\u0131n \u00e7ok nadir g\u00f6r\u00fclen bir yan etkisi olarak kabul etmi\u015fti.<\/p>\n

 <\/p>\n

Wegovy’nin \u00fcreticisi Novo Nordisk ise mevcut verilerin ila\u00e7 ile hastal\u0131k aras\u0131nda bir neden-sonu\u00e7 ili\u015fkisi ortaya koymad\u0131\u011f\u0131 g\u00f6r\u00fc\u015f\u00fcnde olduklar\u0131n\u0131 duyurdu.<\/p>\n

 <\/p>\n

FDA’ya g\u00f6re bu konudaki baz\u0131 ara\u015ft\u0131rmalar\u0131n de\u011ferlendirilmesinde zorluklar ya\u015fand\u0131.<\/p>\n

 <\/p>\n

Bunun nedeni, obezite ve tip 2 diyabet nedeniyle bu ila\u00e7lar\u0131 kullanan ki\u015filerin, ila\u00e7lardan<\/a> ba\u011f\u0131ms\u0131z olarak da NAION i\u00e7in risk fakt\u00f6rlerine sahip olabilmesi.<\/p>\n

Kurum, bu ila\u00e7lar\u0131 kullanan ki\u015filerde g\u00f6z hastal\u0131\u011f\u0131na yakalanma riskinin neden daha y\u00fcksek olabilece\u011finin hen\u00fcz bilinmedi\u011fini belirtti.<\/p>\n

 <\/p>\n

FDA’n\u0131n a\u00e7\u0131klamas\u0131, daha \u00f6nceki ara\u015ft\u0131rmalarda ortaya konan risk tart\u0131\u015fmalar\u0131n\u0131 yeniden g\u00fcndeme getirdi.<\/p>\n

 <\/p>\n

Avrupa \u0130la\u00e7 Ajans\u0131’n\u0131n bir g\u00fcvenlik komitesi de ge\u00e7en y\u0131l yapt\u0131\u011f\u0131 a\u00e7\u0131klamada, Semaglutid kullanan her 10 bin ki\u015fiden en fazla birinin NAION’dan etkilenebilece\u011fini bildirmi\u015fti.<\/p>\n

 <\/p>\n

\u0130ki y\u0131l \u00f6nce yay\u0131mlanan ve 17 bin hastan\u0131n incelendi\u011fi bir ara\u015ft\u0131rmada, Semaglutid kullanan ki\u015filerin NAION te\u015fhisi alma olas\u0131l\u0131\u011f\u0131n\u0131n ilac\u0131 kullanmayanlara k\u0131yasla d\u00f6rt kat daha y\u00fcksek oldu\u011fu tespit edilmi\u015fti.<\/p>\n

 <\/p>\n

Ancak ara\u015ft\u0131rman\u0131n yazarlar\u0131ndan G\u00f6z Hastal\u0131klar\u0131 Profes\u00f6r\u00fc Dr. Joseph Rizzo, bulgular\u0131n “\u00f6nemli ancak hen\u00fcz kesinlik ta\u015f\u0131mad\u0131\u011f\u0131n\u0131” belirterek, ila\u00e7 ile g\u00f6z hastal\u0131\u011f\u0131 aras\u0131ndaki ili\u015fkinin farkl\u0131 hasta gruplar\u0131nda incelenmesi i\u00e7in ek ara\u015ft\u0131rmalara ihtiya\u00e7 oldu\u011funu vurgulam\u0131\u015ft\u0131.<\/p>\n


\n
<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

D\u00fcnyada ve T\u00fcrkiye’de kullan\u0131m\u0131 giderek artan zay\u0131flama i\u011fneleri ve ila\u00e7lar\u0131yla ilgili ABD’den bir uyar\u0131 geldi. \u0130la\u00e7lar\u0131n \u00e7ok nadir de olsa g\u00f6rme kayb\u0131na yol a\u00e7abilece\u011fi belirtiliyor. Amerika Birle\u015fik Devletleri (ABD) G\u0131da ve \u0130la\u00e7 Dairesi FDA Ozempic, Wegovy ve Mounjaro gibi diyabet ve kilo verme tedavisinde kullan\u0131lan ila\u00e7lara yeni bir g\u00fcvenlik uyar\u0131s\u0131 getirdi.   Buna g\u00f6re \u00fcretici […]<\/p>\n","protected":false},"author":908,"featured_media":44139,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"advanced_seo_description":"","jetpack_seo_html_title":"","jetpack_seo_noindex":false,"jetpack_seo_schema_type":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_hide_featured_image":false,"_jetpack_featured_image_duplicate_dismissed":0,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[1],"tags":[],"class_list":["post-44138","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-saglik"],"jetpack_publicize_connections":[],"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"https:\/\/kibrisayna.com\/wp-content\/uploads\/2026\/11\/ZayC4B1flamailacC4B1GLP-1-373055.jpg","_links":{"self":[{"href":"https:\/\/kibrisayna.com\/index.php\/wp-json\/wp\/v2\/posts\/44138","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/kibrisayna.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/kibrisayna.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/kibrisayna.com\/index.php\/wp-json\/wp\/v2\/users\/908"}],"replies":[{"embeddable":true,"href":"https:\/\/kibrisayna.com\/index.php\/wp-json\/wp\/v2\/comments?post=44138"}],"version-history":[{"count":0,"href":"https:\/\/kibrisayna.com\/index.php\/wp-json\/wp\/v2\/posts\/44138\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/kibrisayna.com\/index.php\/wp-json\/wp\/v2\/media\/44139"}],"wp:attachment":[{"href":"https:\/\/kibrisayna.com\/index.php\/wp-json\/wp\/v2\/media?parent=44138"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/kibrisayna.com\/index.php\/wp-json\/wp\/v2\/categories?post=44138"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/kibrisayna.com\/index.php\/wp-json\/wp\/v2\/tags?post=44138"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}